Enliven Therapeutics, Inc. (ELVN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Boulder, CO, United States. El CEO actual es Richard A. Fair.
ELVN tiene fecha de IPO 2020-03-12, 62 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $2.68B.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
